Emerging treatment mechanisms for depression: Focus on glutamate and synaptic plasticity

Drug Discovery Today

Volumn 21, Issue 3, 2016, Pages 454-464

  Gerhard, Danielle M ^a   Wohleb, Eric S ^a   Duman, Ronald S ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; GLUTAMIC ACID; KETAMINE; MONOAMINE OXIDASE INHIBITOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SCOPOLAMINE; TRICYCLIC ANTIDEPRESSANT AGENT; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; AMINO ACID RECEPTOR AFFECTING AGENT; METABOTROPIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; NR2B NMDA RECEPTOR; SCOPOLAMINE BROMIDE;

BRAIN ATROPHY; CHRONIC STRESS; DEPRESSION; DRUG ACTIVITY; DRUG EFFICACY; HUMAN; MAJOR DEPRESSION; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DEPRESSIVE DISORDER, MAJOR; MENTAL STRESS; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; EXCITATORY AMINO ACID AGENTS; GABA-A RECEPTOR AGONISTS; GLUTAMIC ACID; HUMANS; KETAMINE; MUSCARINIC ANTAGONISTS; NEURONAL PLASTICITY; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE; SCOPOLAMINE HYDROBROMIDE; STRESS, PSYCHOLOGICAL;

EID: 84958211581     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.01.016     Document Type: Review

References (101)

1. R.C. Kessler, and et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication Arch. Gen. Psychiatry 62 2005 617 627
2. M.S. Reddy Depression: the disorder and the burden Indian J. Psychol. Med. 32 2010 1 2
3. P.E. Greenberg, and et al. The economic burden of adults with major depressive disorder in the United States (2005 and 2010) J. Clin. Psychiatry 76 2015 155 162
4. D.L. Karch, and et al. Surveillance for violent deaths - National Violent Death Reporting System, 16 states, 2009 MMWR Surveill. Summ. 61 2012 1 43
5. M.H. Trivedi, and et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice Am. J. Psychiatry 163 2006 28 40
6. J. Undurraga, and R.J. Baldessarini Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review Neuropsychopharmacology 37 2012 851 864
7. R.S. Duman, and G.K. Aghajanian Synaptic dysfunction in depression: potential therapeutic targets Science 338 2012 68 72
8. J. Savitz, and W.C. Drevets Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide Neurosci. Biobehav. Rev. 33 2009 699 771
9. N. Li, and et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
10. N. Li, and et al. Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure Biol. Psychiatry 69 2011 754 761
11. R.A. Harrigan, and W.J. Brady ECG abnormalities in tricyclic antidepressant ingestion Am. J. Emerg. Med. 17 1999 387 393
12. A.L. Sharpley, and P.J. Cowen Effect of pharmacologic treatments on the sleep of depressed patients Biol. Psychiatry 37 1995 85 98
13. N. Sussman, and et al. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials J. Clin. Psychiatry 62 2001 256 260
14. P. Birmes, and et al. Serotonin syndrome: a brief review CMAJ 168 2003 1439 1442
15. M. Keller, and et al. Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder Biol. Psychiatry 59 2006 216 223
16. E.P. Zorrilla, and G.F. Koob Progress in corticotropin-releasing factor-1 antagonist development Drug Discov. Today 2010 371 383
17. P.F. Sullivan, and et al. Genetic epidemiology of major depression: review and meta-analysis Am. J. Psychiatry 157 2000 1552 1562
18. B.T. Walsh, and et al. Placebo response in studies of major depression: variable, substantial, and growing JAMA 2002 1840 1847
19. H.S. Mayberg Limbic-cortical dysregulation: a proposed model of depression J. Neuropsychiatry Clin. Neurosci. 9 1997 471 481
20. H.J. Kang, and et al. Decreased expression of synapse-related genes and loss of synapses in major depressive disorder Nat. Med. 18 2012 1413 1417
21. M.T. Treadway, and et al. Illness progression, recent stress, and morphometry of hippocampal subfields and medial prefrontal cortex in major depression Biol. Psychiatry 77 2015 285 294
22. W.C. Drevets, and et al. Glucose metabolism in the amygdala in depression: relationship to diagnostic subtype and plasma cortisol levels Pharmacol. Biochem. Behav. 71 2002 431 447
23. A. Anand, and et al. Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study Biol. Psychiatry 57 2005 1079 1088
24. W.C. Drevets, and et al. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression Brain Struct. Funct. 213 2008 93 118
25. R.M. Shansky, and J.H. Morrison Stress-induced dendritic remodeling in the medial prefrontal cortex: effects of circuit, hormones and rest Brain Res. 1293 2009 108 113
26. C. Liston, and et al. Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting J. Neurosci. 26 2006 7870 7874
27. R.J. Liu, and G.K. Aghajanian Stress blunts serotonin- and hypocretin-evoked EPSCs in prefrontal cortex: role of corticosterone-mediated apical dendritic atrophy Proc. Natl. Acad. Sci. U. S. A. 105 2008 359 364
28. B.S. McEwen, and et al. Stress and anxiety: structural plasticity and epigenetic regulation as a consequence of stress Neuropharmacology 62 2012 3 12
29. K.T. Ota, and et al. REDD1 is essential for stress-induced synaptic loss and depressive behavior Nat. Med. 20 2014 531 535
30. P.J. Lucassen, and et al. Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: Implications for depression and antidepressant action Eur. Neuropsychopharmacol. 20 2010 1 17
31. J. Gronli, and et al. Chronic mild stress inhibits BDNF protein expression and CREB activation in the dentate gyrus but not in the hippocampus proper Pharmacol. Biochem. Behav. 85 2006 842 849
32. A. Nair, and et al. Stressor-specific regulation of distinct brain-derived neurotrophic factor transcripts and cyclic AMP response element-binding protein expression in the postnatal and adult rat hippocampus Neuropsychopharmacology 32 2007 1504 1519
33. H.D. Schmidt, and R.S. Duman Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models Neuropsychopharmacology 35 2010 2378 2391
34. D. Taliaz, and et al. Resilience to chronic stress is mediated by hippocampal brain-derived neurotrophic factor J. Neurosci. 31 2011 4475 4483
35. M.F. Egan, and et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function Cell 112 2003 257 269
36. J.A. Bueller, and et al. BDNF Val66Met allele is associated with reduced hippocampal volume in healthy subjects Biol. Psychiatry 59 2006 812 815
37. F. Soliman, and et al. A genetic variant BDNF polymorphism alters extinction learning in both mouse and human Science 327 2010 863 866
38. L.S. Colzato, and et al. BDNF Val66Met polymorphism is associated with higher anticipatory cortisol stress response, anxiety, and alcohol consumption in healthy adults Psychoneuroendocrinology 36 2011 1562 1569
39. Z.Y. Chen, and et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior Science 314 2006 140 143
40. R.J. Liu, and et al. Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex Biol. Psychiatry 71 2012 996 1005
41. S.S. Pattwell, and et al. The BDNF Val66Met polymorphism impairs synaptic transmission and plasticity in the infralimbic medial prefrontal cortex J. Neurosci. 32 2012 2410 2421
42. K.G. Bath, and et al. BDNF Val66Met impairs fluoxetine-induced enhancement of adult hippocampus plasticity Neuropsychopharmacology 37 2012 1297 1304
43. R.S. Duman, and B. Voleti Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents Trends Neurosci. 35 2012 47 56
44. R.M. Berman, and et al. Antidepressant effects of ketamine in depressed patients Biol. Psychiatry 47 2000 351 354
45. R.S. Duman Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections Dialogues Clin. Neurosci. 16 2014 11 27
46. N.D. Iadarola, and et al. Ketamine and other N-methyl-d-aspartate receptor antagonists in the treatment of depression: a perspective review Ther. Adv. Chronic Dis. 6 2015 97 114
47. H.V. Curran, and C. Morgan Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later Addiction 95 2000 575 590
48. B. Moghaddam, and et al. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J. Neurosci. 17 1997 2921 2927
49. D.S. Lorrain, and et al. Effects of ketamine and N-methyl-D-aspartate on glutamate and dopamine release in the rat prefrontal cortex: modulation by a group II selective metabotropic glutamate receptor agonist LY379268 Neuroscience 117 2003 697 706
50. G.M. Chowdhury, and et al. (1)H-[(1)(3)C]-nuclear magnetic resonance spectroscopy measures of ketamine's effect on amino acid neurotransmitter metabolism Biol. Psychiatry 71 2012 1022 1025
51. A.E. Lepack, and et al. BDNF release is required for the behavioral actions of ketamine Int. J. Neuropsychopharmacol. 18 2015
52. A.E. Autry, and et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses Nature 475 2011 91 95
53. C.A. Hoeffer, and E. Klann mTOR signaling: at the crossroads of plasticity, memory and disease Trends Neurosci. 33 2010 67 75
54. B. Voleti, and et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses Biol. Psychiatry 2013 742 749
55. H. Koike, and et al. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression Behav. Brain Res. 224 2011 107 111
56. J.M. Dwyer, and et al. Ribosomal protein S6 kinase 1 signaling in prefrontal cortex controls depressive behavior Proc. Natl. Acad. Sci. U. S. A. 112 2015 6188 6193
57. M.L. Furey, and W.C. Drevets Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial Arch. Gen. Psychiatry 63 2006 1121 1129
58. S.F. Traynelis, and et al. Glutamate receptor ion channels: structure, regulation, and function Pharmacol. Rev. 62 2010 405 496
59. D.J. Wyllie, and et al. Influence of GluN2 subunit identity on NMDA receptor function Neuropharmacology 2013 4 17
60. H. Monyer, and et al. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors Neuron 12 1994 529 540
61. C.A. Zarate Jr., and et al. A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression Biol. Psychiatry 2013 257 264
62. G. Sanacora, and et al. Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects Mol. Psychiatry 19 2014 978 985
63. C.A. Zarate Jr., and et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression Am. J. Psychiatry 2006 153 155
64. E.S. Gideons, and et al. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses Proc. Natl. Acad. Sci. U. S. A. 111 2014 8649 8654
65. R. Hellweg, and et al. Efficacy of memantine in delaying clinical worsening in Alzheimer's disease (AD): responder analyses of nine clinical trials with patients with moderate to severe AD Int. J. Geriatr. Psychiatry 27 2012 651 656
66. G.A. Mealing, and et al. Differences in degree of trapping of low-affinity uncompetitive N-methyl-d-aspartic acid receptor antagonists with similar kinetics of block J. Pharmacol. Exp. Ther. 288 1999 204 210
67. H.G. Martin, and Y.T. Wang Blocking the deadly effects of the NMDA receptor in stroke Cell 140 2010 174 176
68. S.H. Preskorn, and et al. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder J. Clin. Psychopharmacol. 28 2008 631 637
69. L. Ibrahim, and et al. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder J. Clin. Psychopharmacol. 32 2012 551 557
70. X.L. Zhang, and et al. A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus Neuropharmacology 2008 1238 1250
71. J. Burgdorf, and et al. The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats Neurobiol. Aging 32 2011 698 706
72. J. Burgdorf, and et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects Neuropsychopharmacology 38 2013 729 742
73. C. Duman, and et al. GLYX13 increases mTORC1 signaling and synaptogenesis in the prefrontal cortex 2015
74. S. Preskorn, and et al. Randomized proof of concept trial of GLYX-13, an N-methyl-d-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent J. Psychiatr. Pract. 21 2015 140 149
75. G.E. Crane Cyloserine as an antidepressant agent Am. J. Psychiatry 115 1959 1025 1026
76. U. Heresco-Levy, and et al. Controlled trial of d-cycloserine adjuvant therapy for treatment-resistant major depressive disorder J. Affect. Disord. 93 2006 239 243
77. U. Heresco-Levy, and et al. A randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression Int. J. Neuropsychopharmacol. 16 2013 501 506
78. B-site inhibition J. Pharmacol. Exp. Ther. 355 2015 76 85
79. S. Chaki, and et al. mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants Neuropharmacology 66 2013 40 52
80. S. Chaki, and et al. MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity Neuropharmacology 46 2004 457 467
81. A. Palucha-Poniewiera, and A. Pilc Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test Prog. Neuropsychopharmacol. Biol. Psychiatry 39 2012 102 106
82. E.R. Hascup, and et al. Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex J. Neurochem. 115 2010 1608 1620
83. J.M. Dwyer, and et al. mTOR activation is required for the antidepressant effects of mGluR(2)/(3) blockade Int. J. Neuropsychopharmacol. 15 2012 429 434
84. J.M. Dwyer, and et al. mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure J. Mol. Psychiatry 1 2013 15
85. A. Palucha-Poniewiera, and et al. Activation of the mTOR signaling pathway in the antidepressant-like activity of the mGlu5 antagonist MTEP and the mGlu7 agonist AMN082 in the FST in rats Neuropharmacology 82 2014 59 68
86. W.C. Drevets, and M.L. Furey Replication of scopolamine's antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial Biol. Psychiatry 67 2010 432 438
87. M.L. Furey, and et al. Scopolamine produces larger antidepressant and antianxiety effects in women than in men Neuropsychopharmacology 35 2010 2479 2488
88. J.S. Ellis, and et al. Antidepressant treatment history as a predictor of response to scopolamine: clinical implications J. Affect. Disord. 162 2014 39 42
89. J.C. Gillin, and et al. The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group Biol. Psychiatry 30 1991 157 169
90. M. Amar, and et al. Blockade of different muscarinic receptor subtypes changes the equilibrium between excitation and inhibition in rat visual cortex Neuroscience 169 2010 1610 1620
91. A. Navarria, and et al. Rapid antidepressant actions of scopolamine: role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors Neurobiol. Dis. 82 2015 254 261
92. J.M. Witkin, and et al. M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine J. Pharmacol. Exp. Ther. 2014 448 456
93. A.D. Kramer, and R.J. Feiguine Clinical effects of amitriptyline in adolescent depression. A pilot study J. Am. Acad. Child Psychiatry 20 1981 636 644
94. A receptors Neuropsychopharmacology 2015 (Epub ahead of print)
95. J. Atack, and et al. In vivo labelling of 5 subunit containing GABAA receptors using the selective radioligand [3H]L655,708 Neuropharmacology 49 2005 220 229
96. J. Atack, and et al. L655,708 enhances cognition in rats, but is not proconvulsant at a dose selective for 5 containing GABAA receptors Neuropharmacology 51 2006 1023 1029
97. C. Wang, and et al. Brain damages in ketamine addicts as revealed by magnetic resonance imaging Front. Neuroanat. 2013 23
98. K.A. Lapidus, and et al. A randomized controlled trial of intranasal ketamine in major depressive disorder Biol. Psychiatry 76 2014 970 976
99. M. aan het Rot, and et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression Biol. Psychiatry 67 2010 139 145
100. J.F. Smiley, and P.S. Goldman-Rakic Heterogeneous targets of dopamine synapses in monkey prefrontal cortex demonstrated by serial section electron microscopy: a laminar analysis using the silver-enhanced diaminobenzidine sulfide (SEDS) immunolabeling technique Cereb. Cortex 3 1993 223 238
101. H.X. Wang, and W.J. Gao Cell type-specific development of NMDA receptors in the interneurons of rat prefrontal cortex Neuropsychopharmacology 2009 2028 2040